Prevalence of genetic mutations that predispose to thrombophilia in a Greek Cypriot population

Insights

This study found a high prevalence of thrombogenic mutations, including factor V Leiden and MTHFR mutations, in the Greek-Cypriot population. These genetic predispositions to blood clots warrant consideration for screening, especially before surgery or pregnancy.

Area of Science:

  • Genetics
  • Hematology
  • Molecular Biology

Background:

  • Hereditary disorders affecting anticoagulation are known risk factors for venous thromboembolism.
  • Thrombogenic mutations like factor V Leiden, prothrombin G20210A, and MTHFR C677T are linked to cardiovascular conditions.

Purpose of the Study:

  • To determine the prevalence of three key thrombogenic mutations in an unrelated Greek-Cypriot population.
  • To assess the frequency of factor V Leiden (G1691), prothrombin (G20210A), and MTHFR (C677T) mutations.

Main Methods:

  • Screening of 90 unrelated Greek-Cypriot individuals.
  • Genotyping for specific thrombogenic mutations: factor V Leiden, prothrombin G20210A, and MTHFR C677T.

Main Results:

  • Factor V Leiden mutation: 12.2% heterozygous, 1.1% homozygous.
  • Prothrombin G20210A mutation: 7.8% heterozygous.
  • MTHFR C677T mutation: 44.4% heterozygous, 17.8% homozygous.

Conclusions:

  • Greek-Cypriots exhibit an elevated frequency of thrombogenic mutations.
  • Screening for these mutations is recommended, particularly for individuals planning surgery or pregnancy.
  • This is the first study on thrombophilia risk factor mutation frequency in Cyprus.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
53
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
60
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K